MA39427B1 - Composés pyrrolidine modulateurs de gpr40 pour le traitement de maladies telles que le diabète - Google Patents
Composés pyrrolidine modulateurs de gpr40 pour le traitement de maladies telles que le diabèteInfo
- Publication number
- MA39427B1 MA39427B1 MA39427A MA39427A MA39427B1 MA 39427 B1 MA39427 B1 MA 39427B1 MA 39427 A MA39427 A MA 39427A MA 39427 A MA39427 A MA 39427A MA 39427 B1 MA39427 B1 MA 39427B1
- Authority
- MA
- Morocco
- Prior art keywords
- gpr40
- pyrrolidine
- diabetes
- diseases
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Child & Adolescent Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La présente invention concerne des composés de formule (i) ou un stéréo-isomère, un tautomère, un sel pharmaceutiquement acceptable, un polymorphe ou un solvate desdits composés, toutes les variables de la formule étant telles que définies dans la description. Ces composés sont des modulateurs du récepteur couplé aux protéines g gpr40, qui peuvent être utilisés en tant que médicaments.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461989651P | 2014-05-07 | 2014-05-07 | |
| PCT/US2015/029409 WO2015171722A1 (fr) | 2014-05-07 | 2015-05-06 | Composés pyrrolidine modulateurs de gpr40 pour le traitement de maladies telles que le diabète |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA39427A1 MA39427A1 (fr) | 2017-11-30 |
| MA39427B1 true MA39427B1 (fr) | 2018-09-28 |
Family
ID=53181359
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA39427A MA39427B1 (fr) | 2014-05-07 | 2015-05-06 | Composés pyrrolidine modulateurs de gpr40 pour le traitement de maladies telles que le diabète |
Country Status (33)
| Country | Link |
|---|---|
| US (4) | US9873679B2 (fr) |
| EP (1) | EP3140296B1 (fr) |
| JP (1) | JP6483156B2 (fr) |
| KR (1) | KR102336370B1 (fr) |
| CN (1) | CN106458976B (fr) |
| AR (1) | AR100328A1 (fr) |
| AU (1) | AU2015256120B2 (fr) |
| BR (1) | BR112016024936A2 (fr) |
| CA (1) | CA2948161C (fr) |
| CL (1) | CL2016002809A1 (fr) |
| CY (1) | CY1120340T1 (fr) |
| DK (1) | DK3140296T3 (fr) |
| EA (1) | EA033250B1 (fr) |
| ES (1) | ES2674531T3 (fr) |
| HR (1) | HRP20180641T1 (fr) |
| HU (1) | HUE039288T2 (fr) |
| IL (1) | IL248668B (fr) |
| MA (1) | MA39427B1 (fr) |
| MX (1) | MX378160B (fr) |
| MY (1) | MY181959A (fr) |
| NZ (1) | NZ727146A (fr) |
| PE (1) | PE20161363A1 (fr) |
| PH (1) | PH12016502034B1 (fr) |
| PL (1) | PL3140296T3 (fr) |
| PT (1) | PT3140296T (fr) |
| RS (1) | RS57170B1 (fr) |
| SG (1) | SG11201609170UA (fr) |
| SI (1) | SI3140296T1 (fr) |
| SM (1) | SMT201800342T1 (fr) |
| TN (1) | TN2016000444A1 (fr) |
| TR (1) | TR201809633T4 (fr) |
| TW (1) | TWI659951B (fr) |
| WO (1) | WO2015171722A1 (fr) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015256038B2 (en) * | 2014-05-07 | 2019-07-11 | Bristol-Myers Squibb Company | Pyrrolidine GPR40 modulators for the treatment of diseases such as diabetes |
| DK3140296T3 (en) * | 2014-05-07 | 2018-07-23 | Bristol Myers Squibb Co | PYRROLIDIN GPR40 MODULATORS FOR TREATMENT OF DISEASES SUCH AS DIABETES |
| WO2018049324A1 (fr) | 2016-09-12 | 2018-03-15 | Numerate, Inc. | Composés monocycliques utiles comme modulateurs de gpr120 |
| EP3509588B1 (fr) | 2016-09-12 | 2023-06-07 | Integral Health,Inc. | Composés bicycliques utiles en tant que modulateurs du gpr120 |
| JPWO2018181847A1 (ja) * | 2017-03-31 | 2020-03-05 | 武田薬品工業株式会社 | 芳香環化合物 |
| BR102018007822A2 (pt) | 2017-04-20 | 2018-11-06 | Gilead Sciences, Inc. | composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição |
| CN110772636B (zh) * | 2017-08-21 | 2021-03-16 | 武汉大学 | Gpr31抑制剂在制备治疗心脏缺血再灌注损伤及相关疾病药物中的应用 |
| TWI707849B (zh) | 2018-02-13 | 2020-10-21 | 美商基利科學股份有限公司 | Pd‐1/pd‐l1抑制劑 |
| KR102591947B1 (ko) | 2018-04-19 | 2023-10-25 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
| EP3820572B1 (fr) | 2018-07-13 | 2023-08-16 | Gilead Sciences, Inc. | Inhibiteurs de pd-1/pd-l1 |
| US11236085B2 (en) | 2018-10-24 | 2022-02-01 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
| WO2020113094A1 (fr) | 2018-11-30 | 2020-06-04 | Nuvation Bio Inc. | Composés pyrrole et pyrazole et leurs procédés d'utilisation |
| US11919879B2 (en) | 2021-06-16 | 2024-03-05 | Celgene Corporation | Carboxylic acid containing azetidinyl compounds for the treatment of neurodegenerative diseases |
| CN116283699B (zh) * | 2023-03-02 | 2025-02-11 | 遵义医科大学 | 一种合成氟烷基取代的吡咯烷的方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5614492A (en) | 1986-05-05 | 1997-03-25 | The General Hospital Corporation | Insulinotropic hormone GLP-1 (7-36) and uses thereof |
| KR20120104534A (ko) * | 2009-10-06 | 2012-09-21 | 브리스톨-마이어스 스큅 컴퍼니 | 피롤리딘 ｇｐｒ40 조절제 |
| US7939569B1 (en) * | 2009-12-01 | 2011-05-10 | Hoffmann-La Roche Inc. | Aniline analogs as glycogen synthase activators |
| GB2498976A (en) * | 2012-02-01 | 2013-08-07 | Prosidion Ltd | GPR119 agonists useful in the treatment of type II diabetes |
| EP2880034B1 (fr) | 2012-08-01 | 2016-06-22 | Bristol-Myers Squibb Company | Antagonistes d'amino-hétéroaryle 7-hydroxyspiropipéridine indolinyle du récepteur p2y1 |
| CA2891535A1 (fr) | 2012-11-16 | 2014-05-22 | Bristol-Myers Squibb Company | Modulateurs dihydropyrazoles de gpr40 |
| BR112015010649A2 (pt) * | 2012-11-16 | 2017-07-11 | Bristol Myers Squibb Co | moduladores de gpr40 à base de pirrolidina |
| WO2014078610A1 (fr) | 2012-11-16 | 2014-05-22 | Bristol-Myers Squibb Company | Modulateurs dihydropyrazoles de gpr40 |
| JP6322204B2 (ja) | 2012-11-16 | 2018-05-09 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ジヒドロピラゾールのｇｐｒ４０モジュレーター |
| DK3140296T3 (en) * | 2014-05-07 | 2018-07-23 | Bristol Myers Squibb Co | PYRROLIDIN GPR40 MODULATORS FOR TREATMENT OF DISEASES SUCH AS DIABETES |
| US10301260B2 (en) | 2014-05-07 | 2019-05-28 | Bristol-Myers Squibb Company | Pyrrolidine GPR40 modulators |
| CN106456536B (zh) | 2014-05-07 | 2020-05-12 | 克罗马药品股份有限公司 | 水性眼用溶液和治疗干眼综合征的方法 |
-
2015
- 2015-05-06 DK DK15723095.4T patent/DK3140296T3/en active
- 2015-05-06 CN CN201580022579.4A patent/CN106458976B/zh active Active
- 2015-05-06 AR ARP150101379A patent/AR100328A1/es unknown
- 2015-05-06 PL PL15723095T patent/PL3140296T3/pl unknown
- 2015-05-06 MA MA39427A patent/MA39427B1/fr unknown
- 2015-05-06 SG SG11201609170UA patent/SG11201609170UA/en unknown
- 2015-05-06 NZ NZ727146A patent/NZ727146A/en unknown
- 2015-05-06 TR TR2018/09633T patent/TR201809633T4/tr unknown
- 2015-05-06 HR HRP20180641TT patent/HRP20180641T1/hr unknown
- 2015-05-06 US US14/705,524 patent/US9873679B2/en active Active
- 2015-05-06 MY MYPI2016704054A patent/MY181959A/en unknown
- 2015-05-06 EA EA201692037A patent/EA033250B1/ru not_active IP Right Cessation
- 2015-05-06 SI SI201530232T patent/SI3140296T1/en unknown
- 2015-05-06 MX MX2016013801A patent/MX378160B/es unknown
- 2015-05-06 KR KR1020167033863A patent/KR102336370B1/ko active Active
- 2015-05-06 TW TW104114493A patent/TWI659951B/zh active
- 2015-05-06 CA CA2948161A patent/CA2948161C/fr active Active
- 2015-05-06 HU HUE15723095A patent/HUE039288T2/hu unknown
- 2015-05-06 AU AU2015256120A patent/AU2015256120B2/en active Active
- 2015-05-06 PT PT157230954T patent/PT3140296T/pt unknown
- 2015-05-06 EP EP15723095.4A patent/EP3140296B1/fr active Active
- 2015-05-06 SM SM20180342T patent/SMT201800342T1/it unknown
- 2015-05-06 JP JP2016566651A patent/JP6483156B2/ja active Active
- 2015-05-06 WO PCT/US2015/029409 patent/WO2015171722A1/fr not_active Ceased
- 2015-05-06 PE PE2016002178A patent/PE20161363A1/es unknown
- 2015-05-06 TN TN2016000444A patent/TN2016000444A1/en unknown
- 2015-05-06 RS RS20180504A patent/RS57170B1/sr unknown
- 2015-05-06 BR BR112016024936A patent/BR112016024936A2/pt not_active Application Discontinuation
- 2015-05-06 ES ES15723095.4T patent/ES2674531T3/es active Active
-
2016
- 2016-10-12 PH PH12016502034A patent/PH12016502034B1/en unknown
- 2016-11-01 IL IL248668A patent/IL248668B/en active IP Right Grant
- 2016-11-07 CL CL2016002809A patent/CL2016002809A1/es unknown
-
2017
- 2017-12-13 US US15/840,198 patent/US20180099949A1/en not_active Abandoned
-
2018
- 2018-05-23 CY CY20181100547T patent/CY1120340T1/el unknown
- 2018-12-06 US US16/211,848 patent/US10717725B2/en active Active
-
2020
- 2020-06-08 US US16/895,058 patent/US20200299267A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA39427A1 (fr) | Composés pyrrolidine modulateurs de gpr40 pour le traitement de maladies telles que le diabète | |
| MA39088A1 (fr) | Compositions et procédés pour moduler des récepteurs farnesoïde x | |
| MA39335B1 (fr) | Inhibiteurs mgat2 de dihydropyridinone à substitution tétrazolone | |
| EA201792515A1 (ru) | ЗАМЕЩЕННЫЕ СОЕДИНЕНИЯ ТЕТРАГИДРОХИНОЛИНОНА В КАЧЕСТВЕ МОДУЛЯТОРОВ РЕТИНОИДНЫХ ОРФАНОВЫХ РЕЦЕПТОРОВ ГАММА (RORγ) | |
| EA201791017A1 (ru) | Гидроксисодержащие соединения, модулирующие fxr (nr1h4) | |
| MA39554A3 (fr) | Spirocycloheptanes utilisés en tant qu'inhibiteurs de rock | |
| MA42339A1 (fr) | Modulateurs du récepteur farnésoïde x | |
| MA40302B1 (fr) | Dérivés de carbazole | |
| EA200901098A1 (ru) | Производные тиазола в качестве модуляторов сопряженных с g-белком рецепторов | |
| EA201390969A1 (ru) | Модуляторы глюкагонового рецептора | |
| MX378158B (es) | 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de receptor acoplado a proteina g 139 (gpr139). | |
| MA41041A (fr) | Dérivés de benzothiazole substitués utilisés en tant qu'agonistes de gpr40 pour le traitement du diabète de type ii | |
| EA202091428A1 (ru) | Замещенные амиды ii пирролидина | |
| EA202190272A1 (ru) | Дополнительно замещенные производные триазолохиноксалина | |
| EA202091429A1 (ru) | Замещенные амиды i пирролидина | |
| MA39950B1 (fr) | Dérivé de 2-acylaminothiazole pour le traitement des maladies des voies urinaires et de la vessie | |
| MX362919B (es) | Moduladores del receptor acoplado a proteína-g 120 (gpr120) de ácido biciclo-[2.2.1]. | |
| EA202190271A1 (ru) | Замещенные триазолохиноксалиновые производные | |
| MA43913B1 (fr) | Modulateurs allostériques positifs du récepteur m1 muscarinique | |
| EA202092146A1 (ru) | Производные пиразотетрагидроизохинолина в качестве положительных модуляторов допаминового d1 рецептора | |
| MA39337A1 (fr) | Modulateurs de pyrazines de gpr6 | |
| EA201791480A1 (ru) | Новые производные бензимидазола в качестве антигистаминных агентов | |
| MX2016014118A (es) | Moduladores de receptor de proteina g 40 (gpr40) de pirrolidina para tratamiento de enfermedades tales como diabetes. | |
| MA43231B1 (fr) | Bloqueur des canaux sodiques | |
| SA521431274B1 (ar) | مشتق تتراهيدرو إيزوكينولين بديل كمعدِّل تفارغي إيجابي d1 |